The FDA has delayed a decision on whether it will approve donanemab, Eli Lilly’s closely watched new Alzheimer’s drug, despite promising study results that showed it could significantly slow ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Eli Lilly's senior medical director and associate vice president, respectively. 'Therefore, safety monitoring is necessary with donanemab.' The medication, which patients receive through a ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and ...